Tradestie Institutional Equity Comparison Engine
MYGN vs IMDX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MYGN Overall Edge
MYGN Captures Institutional Edge (4โ0 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Myriad Genetics Inc (MYGN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, MYGN trades at 54.0x Forward P/E with -13.3% operating margin (-1.5% YoY revenue) versus IMDX at N/M Forward P/E and -1883.2% operating margin (+115.0% YoY). In options structure, MYGN sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro) against IMDX sits in BREAKDOWN (12th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
MYGN
MYGN 54.0x vs IMDX N/M Fwd P/E
Growth & Margin Winner
MYGN
Op Margin -13.3% vs -1883.2% ยท YoY -1.5% vs +115.0%
Momentum & Technical Winner
MYGN
1Y -16.4% vs -73.8% ยท 52W Pos 52% vs 3%
Options & Structure Winner
MYGN
CONSOLIDATION (22nd %ile IV) vs BREAKDOWN (12th %ile IV)
MYGN
NASDAQ
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
$5.54
+0.18% 1D
Market Cap
$530.4M
1M Return
-0.54%
1Y Return
-16.44%
Forward P/E
54.0x
Unified AI Score
45.4 / 100
HOLD
Tech 42.0
Fund 48.0
Flow 59.0
Mom 50.0
IMDX
NASDAQ
Insight Molecular Diagnostics Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$1.66
+4.4% 1D
Market Cap
$52.1M
1M Return
-45.03%
1Y Return
-73.78%
Forward P/E
N/M
Unified AI Score
45.5 / 100
HOLD
Tech 50.0
Fund 40.0
Flow 58.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MYGN -16.44%
IMDX -73.78%
Spread: +57.34 pp (MYGN Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MYGN Revenue | IMDX Revenue | MYGN Op. Margin | IMDX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $740M | N/A | 16.4% | N/A | MYGN |
| FY2019 | $850M | N/A | 0.9% | N/A | MYGN |
| FY2020 | $560M | $0M | -52.0% | -2443.3% | MYGN |
| FY2021 | $690M | $0M | -27.6% | -2444.3% | MYGN |
| FY2022 | $680M | $0M | -20.7% | -1878.6% | MYGN |
| FY2023 | $750M | $0M | -34.2% | -1672.4% | MYGN |
| FY2024 | $840M | $0M | -14.7% | -3245.1% | MYGN |
| FY2025 | $820M | $0M | -47.0% | -1260.8% | MYGN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MYGN | IMDX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $530.4M | $52.1M | Larger Scale | MYGN |
| Trailing P/E Ratio Valuation | 54.0x | N/M | Lower Multiple | MYGN |
| Forward P/E Ratio Valuation | 54.0x | N/M | Lower Multiple | MYGN |
| Revenue Growth (YoY) Growth | -1.5% | +115.0% | Higher Growth | IMDX |
| Operating Margin (TTM) Profitability | -13.3% | -1883.2% | Higher Margin | MYGN |
| Net Profit Margin Profitability | -16.1% | 0.0% | Higher Margin | IMDX |
| Return on Equity (ROE) Capital Efficiency | -40.2% | -23603.1% | Higher ROE | MYGN |
| 52-Week Range Position Momentum | 52% ($3โ$8) | 3% ($2โ$8) | Stronger Trend | MYGN |
| Beta / 30D Volatility Risk Regime | 0.63ฮฒ ยท 54% Vol | 2.91ฮฒ ยท 76% Vol | Lower Realized Risk | MYGN |
| Unified Institutional Score Composite Signal | 45.4 / 100 (HOLD) | 45.5 / 100 (HOLD) | Higher Composite | Tie |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MYGN vs IMDX Buy Guide
MYGN
CONSOLIDATION
15d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
22nd %ile
IV Regime
Compressed (<25th %ile)
IMDX
BREAKDOWN
117d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
12th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MYGN nor IMDX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.